Want to see APLM full AI Analyst Report?
Apollomics (APLM) AI Stock Analysis
Apollomics
(NASDAQ:APLM)
The score is primarily weighed down by weak financial performance—persistent losses, continued cash burn, and negative equity—indicating high financing risk. Technicals add further pressure with bearish trend signals and the price below key moving averages, while valuation is constrained by negative earnings and the absence of a dividend yield.
Apollomics (APLM) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $60.75M
- Dividend Yield
- ―
- Average Volume (3M)
- 19.40K
- Price to Earnings (P/E)
- -2.8
- Beta (1Y)
- 0.92
- Revenue Growth
- ―
- EPS Growth
- 86.10%
- Country
- US
- Employees
- 14
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Apollomics Business Overview & Revenue Model
Company Description
Apollomics, Inc., a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to d...
How the Company Makes Money
Apollomics’ primary business model is typical of clinical-stage biopharmaceutical companies: it seeks to create value by advancing drug candidates through clinical trials and monetizing them via (a) partnering transactions and (b) eventual product co...
Apollomics Financial Statement Overview
Summary
Despite a sharp revenue increase in 2025 (~$8.5M vs. ~$0.2M in 2024), the company remains deeply unprofitable (EBIT about -$9.5M; net loss about -$10.9M), free cash flow is still materially negative (~-$10.4M), and the balance sheet weakened with stockholders’ equity turning negative (~-$3.2M). The combination of ongoing losses, continued cash burn, and negative equity implies elevated funding and financial-flexibility risk.
Income Statement
22NegativeBalance Sheet
34NegativeCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.50M | 8.50M | 198.00K | 821.00K | 323.00K | 2,000 |
| Gross Profit | 8.50M | 8.24M | 198.00K | 821.00K | 323.00K | 2,000 |
| EBITDA | -9.36M | -9.22M | -40.77M | -52.88M | -43.29M | -49.59M |
| Net Income | -10.94M | -10.94M | -53.86M | -172.60M | -240.81M | -94.80M |
Balance Sheet | ||||||
| Total Assets | 6.71M | 6.71M | 13.10M | 55.39M | 76.47M | 123.44M |
| Cash, Cash Equivalents and Short-Term Investments | 3.28M | 3.28M | 9.77M | 37.82M | 54.61M | 94.48M |
| Total Debt | 643.00K | 643.00K | 966.00K | 4.66M | 991.00K | 325.41M |
| Total Liabilities | 9.90M | 9.90M | 8.23M | 14.15M | 524.60M | 336.30M |
| Stockholders Equity | -3.19M | -3.19M | 4.86M | 41.23M | -448.12M | -212.86M |
Cash Flow | ||||||
| Free Cash Flow | -17.99M | -10.37M | -28.77M | -43.22M | -43.19M | -50.86M |
| Operating Cash Flow | -17.99M | -10.37M | -28.74M | -43.21M | -42.82M | -43.31M |
| Investing Cash Flow | 266.00K | 218.00K | 5.98M | 21.36M | 29.05M | -38.95M |
| Financing Cash Flow | 3.59M | 3.68M | 468.00K | 21.23M | -294.00K | -1.64M |
Apollomics Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APLM, the sentiment is Negative. The current price of 20.95 is below the 20-day moving average (MA) of 21.25, below the 50-day MA of 23.26, and above the 200-day MA of 18.95, indicating a neutral trend. The MACD of -0.63 indicates Positive momentum. The RSI at 43.95 is Neutral, neither overbought nor oversold. The STOCH value of 32.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APLM.
Apollomics Peers Comparison
Overall Rating
GDTC43Neutral
CLGN41Neutral- APLM41Neutral
HIND40Underperform
XCUR39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| GDTC | 43Neutral | $10.77M | -2.65 | -91.37% | ― | 49.09% | 3.91% |
| CLGN | 41Neutral | $7.71M | -0.44 | -215.58% | ― | -86.76% | 16.63% |
| APLM | 41Neutral | $60.75M | -2.76 | 288.40% | ― | ― | 86.10% |
| HIND | 40Underperform | $12.35M | -0.06 | -254.62% | ― | -97.99% | 99.28% |
| XCUR | 39Underperform | $6.68M | -0.77 | -237.91% | ― | ― | 23.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| APLM | Apollomics Inc. | 20.95 | 8.79 | 72.25% | |
| HIND | Vyome Holdings, Inc. | 1.77 | -4.19 | -70.30% | |
| CLGN | CollPlant Biotechnologies Ltd. | 4.11 | -17.79 | -81.23% | |
| LNAI | Lunai Bioworks, Inc. | 0.16 | -9.20 | -98.25% | |
| XCUR | Exicure | 1.01 | -3.09 | -75.37% | |
| GDTC | CytoMed Therapeutics Limited | 0.91 | -1.20 | -56.87% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 27, 2026